Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.
Also called NCT03001076
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 269 participants
- Sponsor
- Registry
-
NCT03001076
-
- Other papers using this trial's data
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03001076. Randomized; triple masking; primary purpose treatment. Start 2016-11-29 (actual); primary completion 2018-01-11 (actual). Results posted on 2020-04-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Condition
- Hypercholesterolemia
- Condition
- Atherosclerosis
- Condition
- Statin Adverse Reaction
- Intervention (Drug)
- Bempedoic acid
- Intervention (Drug)
- Ezetimibe
- Intervention (Other)
- Placebo
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03001076- Content hash
eed13b5d98f487035995e272c44918413aedc1ba430ee884bbd4f114377b88d4